Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03614650 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immunotherapy Treating GI Cancer

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jul 1, 2025 to Jun 1, 2027
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Study description expanded, about 66 words
    • Site details revised
    v5
  2. Site contact updatedv4
  3. Site contact updatedv3
  4. Primary completion date: Jun 30, 2021 to Jun 30, 2028
    • Start date: Jul 1, 2018 to Jul 1, 2025
    • Study completion date: Dec 31, 2021 to Dec 31, 2028
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objectives are to evaluate the safety and efficacy of infusion of autologous gastro-intestinal (GI) cancer antigen-specific engineered immune effector cells (EIE).
Trial Details
NCT Number NCT03614650
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 Cancer
Related terms Gastrointestinal Neoplasms, Neoplasms
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov